The SARS-CoV-2 was discovered because of Wuhan Viral Pneumonia cases in 2019, and was named by the World Health Organization on January 12, 2020. It belongs to the beta genera of the Coronaviridae family in 2003, together with SARS coronavirus (SARS CoV) in 2003 and MERS coronavirus (MERS CoV) in 2012. The alignment between SARS-CoV-2 and 2002 SARS CoV has about 70% sequence similarity and 40% sequence similarity with MERS CoV. There is currently no specific treatment, but many symptoms can be managed, and need to be treated according to the clinical situation of the patient. Cepham Life Sciences Inc paid close attention to the progression of SARS-CoV-2. Obtaining the virus gene sequence information was the key for developing the SARS-CoV-2 related products. Targets include the Spike protein (S), N protein (N) and ACE2. Moreover, we also provide other products related to coronavirus to meet the needs of scientific research.